High dose oral fluconazole for oropharyngeal candidosis in AIDS

Ansari, Aneel; Gould, Ian M.; Douglas, J. G.

doi:10.1093/jac/25.4.720

Cited by 15 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The remaining 27 publications contain enough information to allow at least some interpretation. All but three (6,57,58) provide information on in vitro susceptibility determined by either the In the typical scenario, a patient with advanced AIDS (CD4 ϩ cell counts were reported in 13 publications and were Ͻ50/mm 3 in the majority of patients [6,10,37,54,57,58,62,68,71,75,76,83,85]) has relapsing oropharyngeal candidiasis that has been treated variously with topical agents or ketoconazole and then finally with either repeated courses of therapy or prolonged therapy with low doses of fluconazole. These therapies are often effective for an extended period of time (estimated at an average of 13 prior relapses in one report [83]), but finally a relapse fails to respond clinically to a course of 100 to 200 mg of fluconazole per day.…”

Section: Reports Of Fluconazole Resistancementioning

confidence: 99%

“…In the other reports of fluconazole-resistant C. albicans in AIDS patients with oropharyngeal and/or esophageal candidiasis, either a relatively high MIC was detected at the time of clinical failure or recurrence (19,26,27,31,37,43,54,68,70,76,78,88), the MIC was stated to be high but actual data were not reported (10), or no MICs were determined (6,57,58). Many of the patients from whom C. albicans strains for which MICs were high were isolated had infections that had failed to respond to prior courses of therapy with other topical (i.e., clotrimazole and nystatin) or systemic (i.e., ketoconazole) agents (19,31,37,76,78,88).…”

Section: Reports Of Fluconazole Resistancementioning

confidence: 99%

See 1 more Smart Citation

Resistance of Candida species to fluconazole

Rex¹,

Rinaldi²,

Pfaller³

1995

Antimicrob Agents Chemother

773

491

View full text Add to dashboard Cite

Section: Reports Of Fluconazole Resistancementioning

confidence: 99%

Section: Reports Of Fluconazole Resistancementioning

confidence: 99%

Resistance of Candida species to fluconazole

Rex¹,

Rinaldi²,

Pfaller³

1995

Antimicrob Agents Chemother

773

491

View full text Add to dashboard Cite

“…Fluconazole (FCZ), an oral triazole with in vivo antifungal activity, has been a convenient and effective treatment for candidiasis (1). However, with the extensive use of FCZ, strains of Candida albicans resistant to FCZ have emerged (10).…”

mentioning

confidence: 99%

Activity of Voriconazole, a New Triazole, Combined with Neutrophils or Monocytes against Candida albicans : Effect of Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor

Vora

Purimetla

Brummer

et al. 1998

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The antifungal activity of voriconazole (VCZ) was tested againstCandida albicans in the absence or presence of polymorphonuclear neutrophils (PMN) or monocytes. In some experiments, VCZ was compared to fluconazole (FCZ). On a weight basis, VCZ was 10-fold more efficacious than FCZ against C. albicans Sh27. Against an FCZ-resistant isolate, VCZ at 1 μg/ml produced the same fungistasis as FCZ at 20 μg/ml. VCZ at 0.1 μg/ml collaborated with PMN for enhanced killing to the same extent as FCZ at 1.0 μg/ml. Granulocyte-colony-stimulating factor (G-CSF) enhanced the candidacidal activity of PMN, and it increased the collaboration of PMN with VCZ for killing. Granulocyte-macrophage (GM)-CSF also significantly enhanced both the killing by PMN and the collaboration of PMN with VCZ for killing. VCZ collaborated with monocytes for enhanced killing ofC. albicans Sh27, and GM-CSF increased this collaboration. Taken together, these data show that VCZ is more potent than FCZ against C. albicans isolates, alone and in collaboration with PMN or monocytes for enhanced killing. In addition, G-CSF- or GM-CSF-activated PMN and monocytes have enhanced collaboration with VCZ compared to that of unstimulated phagocytes with VCZ.

show abstract

“…There is little doubt that the threshold for treatment of possible invasive mycosis has now been lowered (Mangino, Moser & Waites, 1995). In common with other agents such as teicoplanin and ciprofloxacin, higher dosages of fluconazole than were originally recommended are being increasingly used (Ansari, Gould & Douglas, 1990;Bauernfeind, 1993).…”

Section: Discussionmentioning

confidence: 99%

Trends in hospital antibiotic prescribing after introduction of an antibiotic policy

Gould

Jappy²

1996

Journal of Antimicrobial Chemotherapy

Self Cite

View full text Add to dashboard Cite

Trends in antibiotic prescribing in Grampian were monitored prospectively for seven years from 1986 using computerised ward stock lists and laboratory data relating to all in-patient and out-patient treatments in all Grampian hospitals serving a population of 500,000. The main outcome measures were the number of antibiotics available for routine and restricted uses, annual expenditure and defined daily doses (DDDs) of high expenditure antimicrobial agents. An antibiotic committee introduced a policy and formulary in the third year of the study which had only limited success in controlling prescribing. During the period of the study 30 new antibiotics were considered for inclusion in the hospital formulary, but only seven were incorporated, and all for restricted use only. Despite this, expenditure on antibiotics has more than doubled since 1986, two thirds of the increase being due to the use of new drugs. There was also an increased use of older antibiotics (DDDs increased by 33%), often for no clear reasons, and an overall increase of 46% in DDDs. Antibiotics have increased from 11.9-18.7% as a proportion of the drug budget. These findings highlight the current difficulty in controlling prescribing budgets, the increasing use of antibiotics and the consequent spread of resistance.

show abstract

High dose oral fluconazole for oropharyngeal candidosis in AIDS

Cited by 15 publications

References 0 publications

Resistance of Candida species to fluconazole

Resistance of Candida species to fluconazole

Activity of Voriconazole, a New Triazole, Combined with Neutrophils or Monocytes against Candida albicans : Effect of Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor

Trends in hospital antibiotic prescribing after introduction of an antibiotic policy

Contact Info

Product

Resources

About